Additionally, the 36-month beta value for IBIO is 0.98. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for IBIO is 9.31M and currently, short sellers hold a 9.14% ratio of that float. The average trading volume of IBIO on March 27, 2025 was 480.86K shares.
IBIO) stock’s latest price update
iBio Inc (NASDAQ: IBIO)’s stock price has gone rise by 8.11 in comparison to its previous close of 4.31, however, the company has experienced a 2.18% increase in its stock price over the last five trading days. globenewswire.com reported 2025-02-19 that SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody therapies, today announced that iBio’s common stock has been approved for listing on the Nasdaq Capital Market and iBio will transfer its stock exchange listing to Nasdaq Capital Market from the NYSE American. The Company expects to begin trading as a Nasdaq-listed company on Mar 4, 2025, and will continue to trade under the symbol “IBIO.” The Company’s common stock will continue to trade on the NYSE American until the market close on Mar 3, 2025.
IBIO’s Market Performance
iBio Inc (IBIO) has seen a 2.18% rise in stock performance for the week, with a 23.92% gain in the past month and a 97.43% surge in the past quarter. The volatility ratio for the week is 9.85%, and the volatility levels for the past 30 days are at 14.04% for IBIO. The simple moving average for the last 20 days is -10.62% for IBIO’s stock, with a simple moving average of 70.06% for the last 200 days.
Analysts’ Opinion of IBIO
Many brokerage firms have already submitted their reports for IBIO stocks, with Chardan Capital Markets repeating the rating for IBIO by listing it as a “Buy.” The predicted price for IBIO in the upcoming period, according to Chardan Capital Markets is $5 based on the research report published on May 28, 2024 of the previous year 2024.
JMP Securities, on the other hand, stated in their research note that they expect to see IBIO reach a price target of $1.50. The rating they have provided for IBIO stocks is “Mkt Outperform” according to the report published on November 29th, 2021.
Cantor Fitzgerald gave a rating of “Overweight” to IBIO, setting the target price at $3 in the report published on January 22nd of the previous year.
IBIO Trading at 13.75% from the 50-Day Moving Average
After a stumble in the market that brought IBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.38% of loss for the given period.
Volatility was left at 14.04%, however, over the last 30 days, the volatility rate increased by 9.85%, as shares sank -7.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +70.27% upper at present.
During the last 5 trading sessions, IBIO rose by +1.94%, which changed the moving average for the period of 200-days by +92.09% in comparison to the 20-day moving average, which settled at $5.21. In addition, iBio Inc saw 90.18% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IBIO starting from Duran Felipe, who purchase 9,191 shares at the price of $2.72 back on Jan 10 ’25. After this action, Duran Felipe now owns 11,139 shares of iBio Inc, valued at $25,000 using the latest closing price.
Brenner Martin, the insider of iBio Inc, purchase 9,191 shares at $2.72 during a trade that took place back on Jan 10 ’25, which means that Brenner Martin is holding 18,316 shares at $25,000 based on the most recent closing price.
Stock Fundamentals for IBIO
Current profitability levels for the company are sitting at:
- -41.35 for the present operating margin
- 2.1 for the gross margin
The net margin for iBio Inc stands at -51.47. The total capital return value is set at -0.91. Equity return is now at value -123.28, with -51.09 for asset returns.
Based on iBio Inc (IBIO), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -5.16. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is -68.61.
Currently, EBITDA for the company is -14.02 million with net debt to EBITDA at 0.3. When we switch over and look at the enterprise to sales, we see a ratio of 110.47. The receivables turnover for the company is 28.85for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.76.
Conclusion
In conclusion, iBio Inc (IBIO) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
